NCT03486873 2026-03-16
MK-3475-587
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
24 trialsNCT07023289 2026-03-13
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
AbbVie
Phase 2 Recruiting
NCT07155187 2026-03-11
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
Phase 2/3 Recruiting
NCT05316701 2026-03-04
Orca-T
Orca Biosystems, Inc.
Phase 3 Active not recruiting
NCT07206056 2026-03-02
TulmiSTAR-01
Novartis
Phase 1/2 Recruiting
NCT06585410 2026-02-25
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT06855277 2026-02-24
AcTFirst
Novartis
Phase 3 Recruiting
NCT04876651 2026-02-20
The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Terminated
NCT04485949 2026-02-10
A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
Imvax
Phase 2 Active not recruiting
NCT07005102 2026-01-23
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
Phase 2/3 Recruiting
NCT03602859 2025-12-31
FIRST
Tesaro, Inc.
Phase 3 Active not recruiting
NCT03523338 2025-12-10
An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
No longer available
NCT04567420 2025-10-16
DARE
Criterium, Inc.
Phase 2 Recruiting
NCT03778931 2025-09-15
EMERALD
Stemline Therapeutics, Inc.
Phase 3 Completed
NCT04467593 2025-08-05
MATTERS
ElmediX
Phase NA Completed
NCT01711671 2025-08-03
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Leap Therapeutics, Inc.
Phase 1 Completed
NCT03575351 2025-08-03
TRANSFORM
Celgene
Phase 3 Completed
NCT03194646 2025-07-28
ASTEROID 6
Bayer
Phase 3 Terminated
NCT06504524 2025-06-27
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
Pfizer
Completed
NCT06309615 2025-05-29
PDxBRUTILITY
Precise Dx, Inc.
Not yet recruiting
NCT05801965 2025-05-25
A Digital Therapeutic Solution for Cancer Patients
Sidekick Health
Phase NA Completed
NCT06989450 2025-05-25
Digital Patient Support Program for Self-efficacy and Medication Adherence in Women on Adjuvant Endocrine Treatment for Breast Cancer
Sidekick Health
Phase NA Recruiting
NCT06592222 2025-05-20
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies
Pfizer
Completed
NCT06961188 2025-05-07
Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting